PFN2: A Potential Drug Target for Various Diseases (G5217)

Target Name: PFN2

NCBI ID: G5217

PFN2

PFN2: A Potential Drug Target for Various Diseases

PFN2 (D3S1319E), a protein that belongs to the PFN2 subfamily of the protein family N-terminal-type cytoskeletal protein, has been identified as a potential drug target (or biomarker) for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, localization, and function make it an attractive target for small molecule inhibitors.

The protein PFN2 is a 21-kDa protein that is expressed in various tissues and organs, including brain, heart, liver, and muscle. It is highly conserved, with a similar amino acid sequence throughout its length of 120 amino acids. PFN2 is localized to the endoplasmic reticulum (ER) and/or endosomal system, where it can be targeted to specific cellular compartments for different intracellular processes.

PFN2 plays a critical role in the regulation of cellular processes, including cytoskeletal organization, cell adhesion, and intracellular signaling pathways. Its localization to the ER and/or endosomal system suggests that it may be involved in the delivery and processing of proteins to the plasma membrane for cell surface expression. However, its unique structure and function in cytoskeletal organization suggest that it may have additional functions in regulating cellular mechanical forces and cytoskeletal organization.

PFN2 has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has been observed in various types of cancer, including breast, ovarian, and colorectal cancers. It has also been associated with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, its localization to the ER and/or endosomal system suggests that it may be involved in the pathogenesis of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

The potential drug targets for PFN2 are vast, as its unique structure and function make it an attractive target for small molecule inhibitors. Its localization to the ER and/or endosomal system suggests that small molecules with specificity for the ER and/or endosomal system may be effective in inhibiting its function. Additionally, its role in regulating cytoskeletal organization suggests that molecules that can disrupt its structure and stability may be effective in inhibiting its function.

In conclusion, PFN2 is a protein with unique structure and function that is expressed in various tissues and organs and plays a critical role in the regulation of cellular processes, including cytoskeletal organization, cell adhesion, and intracellular signaling pathways. Its localization to the ER and/or endosomal system suggests that it may be involved in the delivery and processing of proteins to the plasma membrane for cell surface expression. Its unique structure and function in cytoskeletal organization make it an attractive target for small molecule inhibitors, and its association with various diseases make it a promising biomarker for diagnostic and therapeutic applications. Further research is needed to fully understand the role of PFN2 in cellular processes and its potential as a drug target.

Protein Name: Profilin 2

Functions: Binds to actin and affects the structure of the cytoskeleton. At high concentrations, profilin prevents the polymerization of actin, whereas it enhances it at low concentrations. By binding to PIP2, it inhibits the formation of IP3 and DG

The "PFN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PFN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets